Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

Arch Ital Urol Androl. 2016 Mar 31;88(1):74-5. doi: 10.4081/aiua.2016.1.74.

Author

Gianpaolo Perletti¹

Affiliation

¹ Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, Università degli Studi dell'Insubria, Busto A., Varese, Italy; Department of Basic Medical Sciences, Ghent University, Ghent. gianpaolo.perletti@uninsubria.it.

PMID: 27072185
DOI: 10.4081/aiua.2016.1.74

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / drug therapy*